Kajsa Radevik

Regulatory CMC Specialist at Novo Nordisk

Speaker

Kajsa Rådevik, MSc, is a Regulatory CMC Specialist at Novo Nordisk, supporting clinical trial applications and CMC-related interactions with health authorities for oligonucleotide programmes. She has 25 years’ pharmaceutical experience, most recently at Novo Nordisk and primarily at AstraZeneca, spanning regulatory CMC, inhalation product development and API process development. Kajsa leads the regulatory subteam of the European Oligonucleotide Consortium, a forum where Regulatory CMC scientists exchange regulatory trends, review guidelines and collaborate on CMC topics with a regulatory focus.